The European Commission has approved Shanghai Junshi Biosciences' (HKG:1877) toripalimab for the treatment of two indications, a Tuesday bourse filing said.
The first indication comprises toripalimab in combination with cisplatin and gemcitabine to treat adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.
The second indication involves toripalimab in combination with cisplatin and paclitaxel for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Shares of the company were up over 3% on Wednesday's close.
Price (HKD): $11.50, Change: $+0.36, Percent Change: +3.23%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。